ValiRx raises ?0.2m through placing with new investors
1st Apr 2020 13:57
(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that it has conditionally raised ?0.2m gross through the issue of 5,714,288 new ordinary shares at a post-reorganisation price of 3.5p each, with new investors.
Read moreValiRx signs letter of intent in a bid to fund VAL401
14th Jan 2020 14:50
(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.
Read moreValiRx granted US patent for 'VAL201' compound
28th Nov 2019 16:13
(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.
Read moreValiRx gets US patent protection for use of VAL201 peptide
26th Jun 2019 10:53
(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.
Read moreValiRx secures 'substantial amendment' to VAL201 clinical trials
20th Jun 2019 09:54
(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.
Read moreValiRx losses widen as it continues to progress drug development
29th May 2019 10:19
(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.
Read moreValiRx acquires IP of failed firm FIT Biotech, forms joint venture
2nd May 2019 09:51
(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.
Read moreValiRx allowed patents for VAL401 in Russia and China
31st Jan 2019 10:08
(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.
Read moreValiRx gives NHS Long Term Plan its seal of approval
9th Jan 2019 14:57
(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.
Read moreVAL401 results accepted for journal publication, says ValiRx
18th Dec 2018 15:53
(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.
Read moreValiRx releases positive data from recent VAL201 testing
10th Dec 2018 11:07
(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Monday that independent analysis of VAL201 data showed a "statistically significant" dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.
Read moreValiRx enters finals stages of clinical trials on VAL201
17th Oct 2018 08:36
(Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.
Read moreValiRx enters 'very exciting' phase for cancer therapies
6th Sep 2018 09:05
(Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.
Read moreValiRx upbeat on positive VAL201 study results
11th Jan 2017 11:18
(ShareCast News) - Clinical stage biotechnology company ValiRx announced positive results in its VAL201 personalised Phase l/II prostate cancer study on Wednesday, adding that with accumulation of safety and tolerability data there is also evidence of disease stabilisation on CT imaging and reductio
Read moreValiRx reports good progress at Georgia drug trial
3rd Nov 2016 11:40
(ShareCast News) - Life science company focused on clinical stage cancer therapeutic development, ValiRx, updated the market on the clinical development of its novel cancer treatment drug, VAL401. The AIM-traded firm said ValiSeek, the joint venture between ValiRx and Tangent Reprofiling, was formed
Read more